Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder
Associated Genetic Biomarkers
NCI Definition: This entity represents a spectrum of lymphoproliferative disorders characterized by CD30 (Ki-1)-positive cutaneous T-cell infiltrates. The two ends of the spectrum include lymphomatoid papulosis (benign end) and primary cutaneous anaplastic large cell lymphoma (malignant end). Borderline lesions are also included in this spectrum. (WHO, 2001) 
There is 1 clinical trial for primary cutaneous CD30-positive T-cell lymphoproliferative disorder, of which 1 is open and 0 are completed or closed. Of the trial that contains primary cutaneous CD30-positive T-cell lymphoproliferative disorder as an inclusion criterion, 1 is phase 1 (1 open).
TNFRSF8 is the most frequent gene inclusion criterion for primary cutaneous CD30-positive T-cell lymphoproliferative disorder clinical trials .
Autologous ccr4-cd30car-cd28-cd3zeta-expressing t-lymphocytes, autologous cd30car-cd28-cd3zeta-expressing t-lymphocytes, and bendamustine are the most common interventions in primary cutaneous CD30-positive T-cell lymphoproliferative disorder clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.